The clinical significance of neopterin and NT-pro BNP in chronic heart failure: a systematic review.

IF 2.1 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Acta cardiologica Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI:10.1080/00015385.2024.2371628

Gaidaa M Dogheim, Mohamed T Amralla, Rehab H Werida

{"title":"The clinical significance of neopterin and NT-pro BNP in chronic heart failure: a systematic review.","authors":"Gaidaa M Dogheim, Mohamed T Amralla, Rehab H Werida","doi":"10.1080/00015385.2024.2371628","DOIUrl":null,"url":null,"abstract":"Background: Biomarkers emerged as powerful adjuncts to conventional clinical care in heart failure (HF). The aim of this study is to evaluate neopterin and NT-pro BNP as diagnostic and prognostic biomarkers in HF.Methods: A systematic search was conducted in six electronic databases from inception to July 24th, 2022. Independent reviewers screened the title, abstract and full text then data extraction and critical appraisal of included studies were performed.Results: A total of eleven studies were included. Neopterin and NT-pro BNP levels were elevated in HF patients as compared to control. Moreover, within HF patients, levels of biomarkers were significantly higher in patients with advanced HF and more severe disease state. Patients who suffered cardiovascular adverse events had high levels of biomarkers. Two studies assessed the effect of treatment on biomarkers levels, showed that levels of neopterin and/or NT-pro BNP decreased with treatment. Studies confirmed the potential of relying on neopterin and NT-pro BNP as diagnostic and prognostic biomarkers in HF in addition to assessing disease severity.Conclusion: Biomarkers levels correlate with disease severity and could be used as diagnostic and prognostic biomarkers in HF. Further research is needed for a definitive conclusion about using these biomarkers to determine the efficacy of therapy.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"720-729"},"PeriodicalIF":2.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta cardiologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00015385.2024.2371628","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Biomarkers emerged as powerful adjuncts to conventional clinical care in heart failure (HF). The aim of this study is to evaluate neopterin and NT-pro BNP as diagnostic and prognostic biomarkers in HF.

Methods: A systematic search was conducted in six electronic databases from inception to July 24th, 2022. Independent reviewers screened the title, abstract and full text then data extraction and critical appraisal of included studies were performed.

Results: A total of eleven studies were included. Neopterin and NT-pro BNP levels were elevated in HF patients as compared to control. Moreover, within HF patients, levels of biomarkers were significantly higher in patients with advanced HF and more severe disease state. Patients who suffered cardiovascular adverse events had high levels of biomarkers. Two studies assessed the effect of treatment on biomarkers levels, showed that levels of neopterin and/or NT-pro BNP decreased with treatment. Studies confirmed the potential of relying on neopterin and NT-pro BNP as diagnostic and prognostic biomarkers in HF in addition to assessing disease severity.

Conclusion: Biomarkers levels correlate with disease severity and could be used as diagnostic and prognostic biomarkers in HF. Further research is needed for a definitive conclusion about using these biomarkers to determine the efficacy of therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

蝶呤和 NT-pro BNP 在慢性心力衰竭中的临床意义：系统综述。

背景：生物标志物已成为心力衰竭（HF）常规临床治疗的有力辅助手段。本研究旨在评估新蝶呤和NT-pro BNP作为心力衰竭诊断和预后生物标志物的作用：方法：从开始到 2022 年 7 月 24 日，在六个电子数据库中进行了系统检索。独立审稿人筛选了标题、摘要和全文，然后对纳入的研究进行了数据提取和批判性评价：结果：共纳入 11 项研究。与对照组相比，心房颤动患者的蝶呤和NT-pro BNP水平升高。此外，在心房颤动患者中，晚期心房颤动患者和病情更严重的患者的生物标志物水平明显更高。发生心血管不良事件的患者的生物标志物水平也较高。两项研究评估了治疗对生物标志物水平的影响，结果显示，新蝶呤和/或NT-pro BNP的水平随治疗而下降。研究证实，除了评估疾病的严重程度外，还可以依靠新蝶呤和NT-pro BNP作为诊断和预后的生物标志物：生物标志物水平与疾病严重程度相关，可用作心房颤动的诊断和预后生物标志物。关于使用这些生物标志物来确定疗效，还需要进一步研究才能得出明确结论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Acta cardiologica 医学-心血管系统

CiteScore

2.50

自引率

12.50%

发文量

115

审稿时长

2 months

期刊介绍： Acta Cardiologica is an international journal. It publishes bi-monthly original, peer-reviewed articles on all aspects of cardiovascular disease including observational studies, clinical trials, experimental investigations with clear clinical relevance and tutorials.